Effect of prolonged dual anti-platelet therapy on reducing myocardial infarction rate after percutaneous coronary

H Q Duan1, P S Dong1, H L Wang1

  • 1The First Affiliated Hospital of Henan University of Science and Technology, Henan, China.

Insights

Prolonged dual anti-platelet therapy after Percutaneous Coronary Intervention (PCI) significantly reduces myocardial infarction rates. Long-term treatment also lowers stent thrombosis risk without increasing serious bleeding events.

Area of Science:

  • Cardiovascular Medicine
  • Interventional Cardiology
  • Pharmacology

Background:

  • Dual anti-platelet therapy (DAPT) is crucial after Percutaneous Coronary Intervention (PCI).
  • The optimal duration of DAPT remains a subject of ongoing research and clinical debate.
  • This review investigates the impact of prolonged DAPT on myocardial infarction and stent thrombosis rates.

Discussion:

  • Meta-analysis of randomized controlled trials indicates a significant reduction in myocardial infarction with long-term DAPT (>6 months) compared to short-term therapy (≤6 months).
  • Observational studies suggest a similar trend for reduced myocardial infarction and a tendency towards lower late stent thrombosis with prolonged DAPT.
  • Importantly, extended DAPT did not correlate with an increased incidence of serious bleeding events.

Key Insights:

  • Long-term DAPT after PCI is associated with a statistically significant decrease in myocardial infarction rates.
  • Prolonged DAPT may reduce the risk of late stent thrombosis, a critical complication post-PCI.
  • The safety profile of long-term DAPT appears favorable, with no significant increase in major bleeding.

Outlook:

  • Further research could explore personalized DAPT duration based on patient-specific risk factors.
  • Investigating novel anti-platelet agents and combinations may offer improved efficacy and safety.
  • Clinical guidelines may evolve to incorporate findings on extended DAPT duration for specific patient populations.

Related Concept Videos

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
1.5K
Peripheral Artery Disease III: Interprofessional Care01:27

Peripheral Artery Disease III: Interprofessional Care

Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
616
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
423
Acute Coronary Syndrome IV: Interprofessional Care01:28

Acute Coronary Syndrome IV: Interprofessional Care

IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
493
Angina IV: Management01:26

Angina IV: Management

IntroductionThe management of angina requires a comprehensive approach that includes pharmacological therapies, medical procedures, and lifestyle modifications.Pharmacological TherapiesAntiplatelet agents, such as aspirin, clopidogrel, prasugrel, and ticagrelor, play a pivotal role in preventing thrombus formation in patients with angina. These medications inhibit platelet aggregation and reduce the likelihood of myocardial infarction and other cardiovascular events.Anticoagulants, including...
441
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
603